EZH2 and lymphoma: SHR2554 is a novel, highly effective, and selective oral EZH2 inhibitor developed by Jiangsu Hengrui Medicine Co., Ltd. It potently inhibits the activity of wild‐type and mutant EZH2 enzymes, thereby affecting intracellular H3K27Me3 levels in lymphoma cells and finally causing cell cycle arrest in the G1 phase.